Show simple item record

dc.contributor.authorGoranova, T
dc.contributor.authorEnnis, D
dc.contributor.authorPiskorz, AM
dc.contributor.authorMacintyre, Geoff
dc.contributor.authorLewsley, LA
dc.contributor.authorStobo, J
dc.contributor.authorWilson, C
dc.contributor.authorKay, D
dc.contributor.authorGlasspool, RM
dc.contributor.authorLockley, M
dc.contributor.authorBrockbank, E
dc.contributor.authorMontes, A
dc.contributor.authorWalther, A
dc.contributor.authorSundar, S
dc.contributor.authorEdmondson, R
dc.contributor.authorHall, GD
dc.contributor.authorClamp, A
dc.contributor.authorGourley, C
dc.contributor.authorHall, M
dc.contributor.authorFotopoulou, C
dc.contributor.authorGabra, H
dc.contributor.authorFreeman, S
dc.contributor.authorMoore, Luiza
dc.contributor.authorJimenez-Linan, M
dc.contributor.authorPaul, J
dc.contributor.authorBrenton, James
dc.contributor.authorMcNeish, IA
dc.date.accessioned2018-11-14T00:32:36Z
dc.date.available2018-11-14T00:32:36Z
dc.date.issued2017-05-09
dc.identifier.issn0007-0920
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/285091
dc.description.abstractBACKGROUND: Investigating tumour evolution and acquired chemotherapy resistance requires analysis of sequential tumour material. We describe the feasibility of obtaining research biopsies in women with relapsed ovarian high-grade serous carcinoma (HGSC). METHODS: Women with relapsed ovarian HGSC underwent either image-guided biopsy or intra-operative biopsy during secondary debulking, and samples were fixed in methanol-based fixative. Tagged-amplicon sequencing was performed on biopsy DNA. RESULTS: We screened 519 patients in order to enrol 220. Two hundred and two patients underwent successful biopsy, 118 of which were image-guided. There were 22 study-related adverse events (AE) in the image-guided biopsies, all grades 1 and 2; pain was the commonest AE. There were pre-specified significant AE in 3/118 biopsies (2.5%). 87% biopsies were fit-for-purpose for genomic analyses. Median DNA yield was 2.87 μg, and was higher in biopsies utilising 14 G or 16 G needles compared to 18 G. TP53 mutations were identified in 94.4% patients. CONCLUSIONS: Obtaining tumour biopsies for research in relapsed HGSC is safe and feasible. Adverse events are rare. The large majority of biopsies yield sufficient DNA for genomic analyses-we recommend use of larger gauge needles and methanol fixation for such biopsies, as DNA yields are higher but with no increase in AEs.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectPeritoneum
dc.subjectOmentum
dc.subjectLiver
dc.subjectLymph Nodes
dc.subjectHumans
dc.subjectCarcinoma
dc.subjectPeritoneal Neoplasms
dc.subjectLiver Neoplasms
dc.subjectOvarian Neoplasms
dc.subjectLymphatic Metastasis
dc.subjectPain
dc.subjectProto-Oncogene Proteins B-raf
dc.subjectDNA, Neoplasm
dc.subjectFeasibility Studies
dc.subjectDNA Mutational Analysis
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectTumor Suppressor Protein p53
dc.subjectProto-Oncogene Proteins p21(ras)
dc.subjectPTEN Phosphohydrolase
dc.subjectPhosphatidylinositol 3-Kinases
dc.subjectClass I Phosphatidylinositol 3-Kinases
dc.subjectNeoplasm Grading
dc.subjectImage-Guided Biopsy
dc.subjectErbB Receptors
dc.titleSafety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
dc.typeArticle
prism.endingPage1301
prism.issueIdentifier10
prism.publicationDate2017
prism.publicationNameBr J Cancer
prism.startingPage1294
prism.volume116
dc.identifier.doi10.17863/CAM.32461
dcterms.dateAccepted2017-03-03
rioxxterms.versionofrecord10.1038/bjc.2017.86
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-05
dc.contributor.orcidMacintyre, Geoff [0000-0003-3906-467X]
dc.contributor.orcidMoore, Luiza [0000-0001-5315-516X]
dc.contributor.orcidBrenton, James [0000-0002-5738-6683]
dc.identifier.eissn1532-1827
rioxxterms.typeJournal Article/Review
pubs.funder-project-idCancer Research UK (A15973)
pubs.funder-project-idCancer Research UK (A15601)
cam.issuedOnline2017-03-30


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-ShareAlike 4.0 International